Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAEnriqueta Felip, S.-H. Lee, Y. Shinno et al.|Annals of Oncology|2024Cited by 81
Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II studyHyun Ae Jung, Jong‐Mu Sun, Sojung Park et al.|ESMO Open|2023Cited by 16
P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)B.C. Cho, D.-W. Kim, S.-H. Lee et al.|Journal of Thoracic Oncology|2022Cited by 7
MA07.04 Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLCM.E. Marmarelis, B.C. Cho, S.-H. Lee et al.|Journal of Thoracic Oncology|2022Cited by 4
MA13.06 Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2S.-H. Lee, M.E. Marmarelis, Byoung Chul Cho et al.|Journal of Thoracic Oncology|2023Cited by 4